Literature DB >> 9461325

Integrins in thyroid tissue: upregulation of alpha2beta1 in anaplastic thyroid carcinoma.

T Dahlman1, L Grimelius, G Wallin, K Rubin, K Westermark.   

Abstract

OBJECTIVE: To evaluate the integrin pattern in the normal thyroid gland and in different pathological disorders including malignant tumors, because the aggressiveness of several malignant tumors correlates with alterations in the expression of one or more integrins.
DESIGN: We examined the expression of integrins and E-cadherin immunohistochemically in a large and well-defined sample of normal and pathological human thyroid tissue.
METHODS: Cryosections of 58 thyroid tissue specimens from normal tissue, thyrotoxicosis, nodular goiter, oxyphilic adenoma, follicular adenoma, follicular carcinoma, papillary carcinoma and anaplastic carcinoma, and three lymph node metastases were investigated immunohistochemically using monoclonal antibodies specifically recognizing the integrin beta1-, beta4-, alpha1-, alpha2-, alpha3-, alpha5- and alpha6-subunits, or E-cadherin.
RESULTS: All thyroid epithelial cells expressed integrin beta1- and alpha3-subunits. Immunostaining of the beta4-subunit and the alpha6-subunits was found only in tumors. The staining pattern in the three lymph node metastases from papillary carcinomas did not differ from that in their primaries. Anaplastic carcinomas demonstrated neoexpression of the integrin alpha2-subunit. E-cadherin was detected in all tissues except anaplastic carcinomas.
CONCLUSIONS: Neoexpression of alpha6beta4 was seen in most malignant tumors, whereas alpha2 was exclusively found in anaplastic carcinomas. In the latter, a loss of E-cadherin expression was also seen. These changes in cell adhesion molecule expression strongly suggest an association with the acquisition of proliferative and invasive properties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461325     DOI: 10.1530/eje.0.1380104

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

Review 2.  The cell biology of the thyroid-disrupting mechanism of dichlorodiphenyltrichloroethane (DDT).

Authors:  M Rossi; A R Taddei; I Fasciani; R Maggio; F Giorgi
Journal:  J Endocrinol Invest       Date:  2017-06-21       Impact factor: 4.256

Review 3.  Clinical significance of the integrin α6β4 in human malignancies.

Authors:  Rachel L Stewart; Kathleen L O'Connor
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

Review 4.  Molecular testing in the diagnosis of differentiated thyroid carcinomas.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Salvatore Ulisse; Enke Baldini; Riccardo Giannini; Paolo Miccoli; Alessandro Antonelli; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

5.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Authors:  Shweta Kotian; Lisa Zhang; Myriem Boufraqech; Kelli Gaskins; Sudheer Kumar Gara; Martha Quezado; Naris Nilubol; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

6.  Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.

Authors:  Changxue Lu; Li Zhao; Hao Ying; Mark C Willingham; Sheue-Yann Cheng
Journal:  Endocrinology       Date:  2010-02-04       Impact factor: 4.736

Review 7.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

8.  Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Authors:  Lisa Zhang; Yaqin Zhang; Amit Mehta; Myriem Boufraqech; Sean Davis; Jing Wang; Ze Tian; Zhiya Yu; Matthew B Boxer; Jeffrey A Kiefer; John A Copland; Robert C Smallridge; Zhuyin Li; Min Shen; Electron Kebebew
Journal:  Oncotarget       Date:  2015-04-20

9.  A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells.

Authors:  Guanhua Li; Zuojun Hu; Henghui Yin; Yunjian Zhang; Xueling Huang; Shenming Wang; Wen Li
Journal:  Int J Nanomedicine       Date:  2013-03-27

10.  The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines.

Authors:  Weiwei Cheng; Fang Feng; Chao Ma; Hui Wang
Journal:  Onco Targets Ther       Date:  2016-03-11       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.